In the last decades,α-GLY inhibitors named acarbose, miglitol,and voglibose have been clinically approved in the management of T2DM.The undesirable adverse gastrointestinal effects of these carbohydratemimic-based α-GLY inhibitors have limited their clinical applications.14,15 In the last years, researchers showed an extensive effort to discoversynthetic α-GLY inhibitors with better efficacy and minimalside effects. Here, SHMT2 is linked to type 2 diabetes mellitus.